title: Global improvement of systemic scleroderma under long-term administration of octreotide.
abstract: Octreotide has proven to be effective for the treatment of intestinal dysmotility in patients with scleroderma in short-term administration. We report a global improvement of scleroderma manifestations under long-term administration of octreotide. A 53-year-old black woman was diagnosed with a four-year history of progressive and severe systemic scleroderma, with diffuse skin sclerosis, myositic involvement, impaired carbon monoxide transfer factor (57% of the predicted normal value and severe digestive involvement with pseudo-obstruction and bacterial overgrowth into the intestinal lumen). After one month of octreotide (75 mug/d), oral feeding was restarted and weight gain of 6.5 kg was achieved. After 8 months of treatment, normal weight was obtained and skin induration was spectacularly reduced and pigmentation returned to a normal state. Dyspnea disappeared and physical activity was quite normal. Octreotide effects on intestinal transit are unclear and may be secondary to immunomodulation or neurotransmission effects. Extradigestive effects of octreotide in scleroderma have not been studied. This report suggests that long-term administration of octreotide may be beneficial in the treatment of patients with systemic scleroderma. Long-term trials are required to confirm these preliminary results.
authors.affiliation: Department of Dermatology, Hôpital Bichat, 75018 Paris, France. vincent.descamps@bch.ap-hop-paris.fr
authors.forename: V
authors.initials: V
authors.lastname: Descamps
authors.forename: X
authors.initials: X
authors.lastname: Duval
authors.forename: B
authors.initials: B
authors.lastname: Crickx
authors.forename: F
authors.initials: F
authors.lastname: Bouscarat
authors.forename: B
authors.initials: B
authors.lastname: Coffin
authors.forename: S
authors.initials: S
authors.lastname: Belaich
mesh_terms: D000284:Administration, Oral; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D008134:Long-Term Care; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D012595:Scleroderma, Systemic / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D005765:Gastrointestinal Agents; D015282:Octreotide